ArticleJournal of bioenergetics and biomembranes2026
PTGS2 as a potential target for apigenin to promote spinal cord injury repair.
Article in Journal of bioenergetics and biomembranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Spinal cord injury (SCI) is characterized by damage to the spinal cord caused by various reasons, and there is a lack of effective drug treatments. Apigenin, a well-known natural small molecule drug, may serve as a therapeutic agent for a variety of diseases. However, the potential mechanisms by which Apigenin exerts its effects in SCI remain unclear. By utilizing an integrative multiomics strategy that combines network pharmacology, Mendelian randomization, and single-cell transcriptomic profiling, we established a systems-level target identification framework. Mechanistic analysis revealed a phytochemical‒neuropathy interactome, causal inference modeling (SMR) revealed target‒phenotype linkages and single-cell spatial mapping revealed the localization of target neural cell subtypes. In vitro experiments using PC12 cells and primary neuronal cells further validated the protective effects of apigenin against H2O2-induced neuronal injury. The results demonstrated that PTGS2, a key target identified through integrated analyses, exhibited elevated expression in SCI neurons. Apigenin treatment effectively mitigated H2O2-induced cellular damage while decreasing PTGS2 expression. These findings confirm that PTGS2 is a potential therapeutic target in SCI and highlight the value of a multiomics approach in overcoming traditional methodological limitations related to specificity and resolution. This study provides critical insights for advancing the clinical translation of apigenin and natural drug development strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.